MetaVia

MetaVia ROE

The Return on Equity (ROE) of MetaVia (MTVA) as of Oct 30, 2026 is -243.26 %. In the previous year, Return on Equity (ROE) was -347.90 % — a change of -30.08% (higher).

ROE

-243.26 %

YoY

-30.08%

Last updated:

In 2025, MetaVia's return on equity (ROE) was -243.26 %, a -30.08% increase from the -347.90 % ROE in the previous year.

The MetaVia ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
116.88 USD
Jan 1, 2019
-173.38 USD
Jan 1, 2020
-412.02 USD
Jan 1, 2021
-104.71 USD
Jan 1, 2022
-64.22 USD
Jan 1, 2023
-74.74 USD
Jan 1, 2024
-347.90 USD
Jan 1, 2025
-243.26 USD
The MetaVia ROE history
YEARROEYoY
-243.26 %-30.08%
-347.90 %+365.49%
-74.74 %+16.38%
-64.22 %-38.67%
-104.71 %-74.59%
-412.02 %+137.64%
-173.38 %-248.34%
116.88 %-113.79%
-847.88 %+1,099.33%
-70.70 %-196.93%
72.93 %+21.02%
60.26 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MetaVia Stock analysis

What does MetaVia do? NeuroBo Pharmaceuticals, Inc. generates revenue by developing novel pharmaceuticals to address unmet medical needs in patients suffering from neurodegenerative disorders. The company focuses on specific therapeutic areas including Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease, targeting these conditions with its proprietary product candidates. This strategy allows the firm to serve the clinical-stage biotechnology market by offering specialized treatments for serious health conditions. The company’s product portfolio includes NB-01, which is designed to target neuropathic pain with an indication for PDN, and NB-02, a drug developed for Alzheimer’s and tauopathies. Additionally, the firm offers Gemcabene, a therapy focused on treating dyslipidemia, a condition that increases the risk of life-threatening cardiovascular disease. Gemcabene is specifically directed at orphan indications such as homozygous familial hypercholesterolemia (HoFH) and severe hypertriglyceridemia (SHTG). Furthermore, NeuroBo Pharmaceuticals, Inc. is developing a capsule formulation of niclosamide for coronavirus indications. By expanding its research into these diverse medical conditions, the company aims to provide comprehensive pharmaceutical solutions. The firm operates from its headquarters in Boston, Massachusetts, and maintains a focused development pipeline to bring these treatments to market. MetaVia is one of the most popular companies on Eulerpool.

ROE Details

Decoding MetaVia's Return on Equity (ROE)

MetaVia's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing MetaVia's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

MetaVia's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in MetaVia’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about MetaVia stock

Return on Equity (ROE) of MetaVia is -243.26 % in 2025.

Return on Equity (ROE) of MetaVia changed from -347.90 % to -243.26 %, representing a -30.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) MetaVia since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s MetaVia with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — MetaVia

All Key Metrics — MetaVia